Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 2;15:1947. doi: 10.1038/s41467-024-46180-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Relative GREB1 and FOXO1 mRNA abundance in human endometrial stromal cells transfected with control or GREB1 siRNA and treated with MPA or vehicle for 4 hr. Analyzed by one-way ANOVA with Tukey’s multiple comparisons post-test. Data reported as the mean ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001. b Relative GREB1 and PR protein concentrations in human endometrial stromal cells transfected with control or GREB1 siRNA and treated with vehicle or MPA. Right side panel depicts the GREB1 protein quantification. GAPDH serves as a loading control. Analyzed by one-way ANOVA with Tukey’s multiple comparisons post-test. Data reported as the mean ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001. c PCR products amplified with the indicated FOXO1 primers (shown in map in Supplementary Fig 1a, after immunoprecipitating DNA with anti-GREB1 or anti-PR antibody. UNTR, untranscribed region. d ChIP-qPCR validation of PR binding on the FOXO1 region in HESCs treated with control siRNA or GREB1 siRNA prior to 4 hr MPA treatment. Data are represented as fold enrichment of IgG and PR over that of the negative control region. Analyzed by one-way ANOVA with Tukey’s multiple comparisons post-test. Data reported as the mean ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001. e Whole-cell lysates isolated from human endometrial stromal cells treated with 1 µM MPA or vehicle for 4 h, immunoprecipitated with PR antibody or control IgG, and immunoblotted with GREB1 (top panel) or PR (bottom panel) antibody. Data are presented as the mean ± SEM from three biological replicates from a representative experiment (experiment repeated three times). *P < 0.05, **P < 0.01, ***P < 0.001. f The heatmap of GREB1 binding peaks from HESCs using CUT&RUN sequencing analysis. g IGV track visualization of GREB1 peaks on DUSP10 and PHF20 gene clusters. h Venn diagrams illustrating the overlap between GREB1 and PR peaks (left) and called genes (right) from the GREB1 and PR cistromes.